Tech Company Financing Transactions
CellsBin Funding Round
CellsBin closed a Series A funding round on 9/22/2026. Investors included 108 BioCapital and private investors.
Transaction Overview
Company Name
Announced On
9/22/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
108 BioCapital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate commercialization, strategic partnerships, product development and expansion of its clinical and technical capabilities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 College St
New Haven, CT 06510
USA
New Haven, CT 06510
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
CellsBin is a technology-bio company combining photonics, AI, and translational science to make rare cells visible and turn them into actionable clinical insight. Clinicians still lack a reliable way to detect and understand the rare cells that can determine disease progression, treatment response, and relapse--limiting their ability to act early and with confidence. We believe Rare-Cell Biology� is a foundational layer of precision medicine: when low-abundance cells become visible, measurable, and biologically understood, their signals can be translated into actionable clinical decisions that improve how medicine treats patients.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 9/22/2026: Primo venture capital transaction
Next: 9/22/2026: Zeliq venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








